Anti-amyloid immunotherapy

Layer 3 — Biologyin the Neurodegenerative Disease subtree

Aducanumab FDA 2021 (controversial accelerated approval), lecanemab 2023 (Clarity-AD trial showed slowed cognitive decline), donanemab 2024.

Related concepts